Disruption of the Th17/Treg balance is an important factor in IBD pathogenesis and blocking the Th17 axis, either by directly inhibiting IL-17 directly or via preventing Th17 cell differentiation,is currently an area of intense therapeutic development [49]. Here, IL17A is linked to inflammatory bowel disease.